BioCentury
ARTICLE | Clinical News

APF530: Preliminary Phase III data

October 6, 2008 7:00 AM UTC

AP Pharma released top-line results from a double-blind, double-dummy, international Phase III trial in 1,395 patients receiving moderately or highly emetic chemotherapy, comparing 5 mg and 10 mg subc...